Image

Global Polycystic Kidney Disease (PKD) Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Polycystic Kidney Disease (PKD) Market, By Type (Autosomal Dominant Polycystic Kidney Disease, Autosomal Recessive Polycystic Kidney Disease, Others), Treatment (Medication, Surgery, Others), Diagnosis (Ultrasound, CT Scan, MRI Scan), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2029.

Polycystic Kidney Disease (PKD) Market

Global Polycystic Kidney Disease (PKD) Market Analysis and Size

In recent years, the polycystic kidney disease (PKD) market is anticipated to grow rapidly during the forecast period owing to the rising prevalence of kidney disorders. Polycystic kidney disease is caused by genetic abnormalities. In the majority of cases, the disorder is passed down to the children by their parents. As a result, you are born with PKD. However, genes can mutate or change at any time.

  • Data Bridge Market Research analyses that the polycystic kidney disease (PKD) market was valued at USD 450.55 million in 2021 and is expected to reach USD 732.32 million by 2029, registering a CAGR of 6.26% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Global Polycystic Kidney Disease (PKD) Market Definition

The genetic ailment polycystic kidney disease (PKD) causes cysts to form in the kidneys, causing them to malfunction. High blood pressure and renal failure are two health problems. PKD is a kind of chronic kidney disease that is very dangerous. Cysts can enlarge the kidneys, making it difficult for them to filter waste from the blood.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Autosomal Dominant Polycystic Kidney Disease, Autosomal Recessive Polycystic Kidney Disease, Others), Treatment (Medication, Surgery, Others), Diagnosis (Ultrasound, CT Scan, MRI Scan), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Johnson & Johnson Private Limited (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), AbbVie Inc. (US), Novartis AG (Switzerland), Taro Pharmaceutical Industries Ltd. (US), Otsuka Pharmaceutical Co., Ltd. (Japan), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), CorePharma LLC (US), Hikma Pharmaceuticals Plc (UK), Kadmon Holdings Inc. (US), Reata Pharmaceuticals Inc. (US), Merck & Co., Inc. (US), AstraZeneca (UK)

Market Opportunities

 

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Polycystic Kidney Disease (PKD) Market Dynamics

Drivers

  • Increasing Incidences of Kidney Failure 

The polycystic kidney disease market is driven by an increase in incidences of renal failure or dialysis. Polycystic kidney disease can be caused by a number of factors, including a family history of kidney problems, a rare genetic mutation, kidney failure, or people on dialysis, all of which will raise the polycystic kidney disease market.     

  • Increasing Investment for Healthcare Infrastructure

Another significant factor influencing the growth rate of polycystic kidney disease (PKD) market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the polycystic kidney disease (PKD) market. Additionally, high disposable income and rising demand for advanced treatment and innovative solutions will result in the expansion of polycystic kidney disease (PKD) market. Along with this, favourable government policies and rising awareness about genetic diseases among people will enhance the growth rate of the market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the polycystic kidney disease (PKD) market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the polycystic kidney disease (PKD) market growth during the forecast period.

Restraints/Challenges Global Polycystic Kidney Disease (PKD) Market

On the other hand, the high cost associated with the treatment of polycystic kidney disease (PKD) will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the polycystic kidney disease (PKD) market. Additionally, impact of COVID-19 on supply chain and the dearth of awareness will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This polycystic kidney disease (PKD) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the polycystic kidney disease (PKD) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

PKD affects about 500,000 persons in the United States. PKD is responsible for around 2% of all kidney failure cases. PKD can affect people of various ages, races, and ethnicities. It affects both men and women equally.

Polycystic kidney disease (PKD) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Polycystic Kidney Disease (PKD) Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of polycystic kidney disease (PKD) in recent months.

Global Polycystic Kidney Disease (PKD) Market Scope

The polycystic kidney disease (PKD) market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Autosomal Dominant Polycystic Kidney Disease
  • Autosomal Recessive Polycystic Kidney Disease
  • Others

On the basis of type, the polycystic kidney disease market is segmented into autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney disease and others.

Treatment

On the basis of treatment, the polycystic kidney disease market is segmented into medication, surgery and others.

Diagnosis

  • Ultrasound
  • CT Scan
  • MRI Scan

On the basis of diagnosis, the polycystic kidney disease market is segmented into ultrasound, CT scan, and MRI scan.

Route of Administration

  • Oral
  • Parenteral
  • Others

Route of administration segment of polycystic kidney disease market is segmented into oral, parenteral and others.

End-Users

  • Hospitals
  • Specialty Clinics
  • Others

On the basis of end-users, the polycystic kidney disease market is segmented into hospitals, specialty clinics and others.

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

On the basis of distribution channel, the polycystic kidney disease market has also been segmented into hospital pharmacy, retail pharmacy, and others

Polycystic Kidney Disease (PKD) Market Regional Analysis/Insights

The polycystic kidney disease (PKD) market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the polycystic kidney disease (PKD) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the polycystic kidney disease (PKD) market because of the advancement in technology and growing number of government initiatives taken by pharmaceutical organizations to generate novel formulation in this region. 

Asia-Pacific is expected to grow during the forecast period due to rising number of government initiatives for spread awareness and presence of generic manufacturer in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Polycystic Kidney Disease (PKD) Market Share Analysis

The Polycystic kidney disease (PKD) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to polycystic kidney disease (PKD) market.

Some of the major players operating in the polycystic kidney disease (PKD) market are:

  • Johnson & Johnson Private Limited (US)
  • Mylan N.V. (US)
  • Teva Pharmaceutical Industries Ltd.(Jerusalem)
  • Sanofi (France)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • AbbVie Inc. (US)
  • Novartis AG (Switzerland)
  • Eli Lilly and Company (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Merck & Co., Inc. (US)
  • Taro Pharmaceutical Industries Ltd. (US)
  • Otsuka Pharmaceutical Co., Ltd. (Japan)
  • CorePharma LLC (US)
  • Hikma Pharmaceuticals Plc (UK)
  • Kadmon Holdings Inc. (US)
  • Reata Pharmaceuticals Inc. (US)
  • AstraZeneca (UK)

Research Methodology : Global Polycystic Kidney Disease (PKD) Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available : Global Polycystic Kidney Disease (PKD) Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The Market Value for Polycystic Kidney Disease (PKD) Market is expected USD 732.32 million by 2029.
The Polycystic Kidney Disease (PKD) Market is to Grow at a CAGR of 6.26% During the Forecast Period of 2022 to 2029.
Johnson & Johnson Private Limited (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland) are the Major Companies Operating in Polycystic Kidney Disease (PKD) Market.
The Countries Covered in the Polycystic Kidney Disease (PKD) Market Report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
The Polycystic Kidney Disease (PKD) Market Report Curated by the Data Bridge Market Research Team Includes In-Depth Expert Analysis, Patient Epidemiology, Pipeline Analysis, Pricing Analysis, and Regulatory Framework.